Xenon up-regulates several genes that are not up-regulated by nitrous oxide

Journal of Neurosurgical Anesthesiology

Volumn 20, Issue 4, 2008, Pages 226-232

  Valleggi, Simona ^a   Cavazzana, Andrea O ^a   Bernardi, Rodolfo ^c   Daqing, Ma ^e   Natale, Gianfranco ^c   Maze, Mervyn ^e   Davide, Cattano ^b,c,d   Giunta, Francesco ^b  

^a UNIVERSITY OF PISA   (Italy)

^b Department of Surgery   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anesthesia preconditioning; Gene transcription; Neuroprotection; Suppression subtractive hybridization

Indexed keywords

NITROGEN; NITROUS OXIDE; OXYGEN; XENON; COMPLEMENTARY DNA; INHALATION ANESTHETIC AGENT; NERVE PROTEIN; RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; INHALATION ANESTHESIA; ISCHEMIC PRECONDITIONING; NEUROPROTECTION; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; UNINDEXED SEQUENCE; UPREGULATION; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

ANESTHETICS, INHALATION; ANIMALS; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; DNA, COMPLEMENTARY; ISCHEMIC PRECONDITIONING; NERVE TISSUE PROTEINS; NITROUS OXIDE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; UP-REGULATION; XENON;

EID: 58949104325     PISSN: 08984921     EISSN: None     Source Type: Journal    
DOI: 10.1097/ANA.0b013e31817da878     Document Type: Article

References (43)

1. Sanders RD, Ma D, Maze M. Xenon: elemental anaesthesia in clinical practice. Br Med Bull. 2005;71:115-135. Review.
2. Ma D, Hossain M, Chow A, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol. 2005;58:182-193.
3. Preckel B, Weber NC, Sanders RD, et al. Molecular mechanisms transducing the anesthetic, analgesic, and organ-protective actions of xenon. Anesthesiology. 2006;105:187-197.
4. Homi HM, Yokoo N, Ma D, et al. The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology. 2003;99:876-881.
5. David HN, Haelewyn B, Rouillon C, et al. Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J. 2008;22:1275-1286.
6. Abraini JH, David HN, Lemaire M. Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon. Ann NY Acad Sci. 2005;1053:289-300.
7. Ma D, Hossain M, Pettet GKJ, et al. Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. J Cereb Blood Flow Metab. 2006;26:199-208.
8. Chirgwin JM, Przybyla AE, MacDonald RJ, et al. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294-5299.
9. Diatchenko L, Lau Y-FC, Campbell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA. 1996;93:6025-6030.
10. Traina G, Valleggi S, Bernardi R, et al. Identification of differentially expressed genes induced in the rat brain by acetylL-carnitine as evidenced by suppression subtractive hybridisation. Brain Res Mol Brain Res. 2004;132:57-63.
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCT method. Methods. 2001;25:402-408.
12. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucl Acids Res. 2002;30:e36.
13. Yuan JS, Reed A, Chen F, et al. Statistical analysis of real-time PCR data. BMC Bioinform. 2006;22:7-85.
14. Jevtović-Todorović V, Todorović SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4:460-463.
15. Ma D, Williamson P, Januszewski A, et al. Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain. Anesthesiology. 2007;106:746-753.
16. Cattano D, Williamson P, Fukui K, et al. Potential of xenon to induce or protect against neuroapoptosis in the developing mouse brain. Can J Anesth. In press.
17. Franks NP, Dickinson R, de Sousa SL, et al. How does xenon produce anaesthesia? Nature. 1998;396:324.
18. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503-513.
19. Natale G, Cattano D, Abramo A, et al. Morphological evidence that xenon neuroprotects against N-methyl-DL-aspartic acid-induced damage in the rat arcuate nucleus: a time-dependent study. Ann NY Acad Sci. 2006;1074:650-658.
20. Muller BM, Kistner U, Kindler S, et al. SAP102, a novel postsynaptic protein that interacts with NMDA receptor complexes in vivo. Neuron. 1996;17:255-265.
21. Sans N, Prybylowski K, Petralia RS, et al. NMDA receptor trafficking through an interaction between PDZ proteins and the exocyst complex. Nat Cell Biol. 2003;5:520-530.
22. Washbourne P, Liu XB, Jones EG, et al. Cycling of NMDA receptors during trafficking in neurons before synapse formation. J Neurosc. 2004;24:8253-8264.
23. Bock JB, Matern HT, Peden AA, et al. A genomic perspective on membrane compartment organization. Nature. 2001;409:839-841.
24. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol. 2001;2:107-117.
25. Proikas-Cezanne T, Gaugel A, Frickey T, et al. Rab14 is part of the early endosomal clathrin-coated TGN microdomain. FEBS Lett. 2006;580:5241-5246.
26. Franks NP, Honoré E. The TREK K2P channels and their role in general anaesthesia and neuroprotection. Trends Pharmacol Sci. 2004;25:601-608.
27. Gruss M, Bushell TJ, Bright DP, et al. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol. 2004;65:443-452.
28. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998;67:481-507.
29. Suh BC, Hille B. Regulation of ion channels by phosphatidylinositol 4,5-bisphosphate. Curr Opin Neurobiol. 2005;15:370-378.
30. Chemin J, Patel AJ, Duprat F, et al. A phospholipid sensor controls mechanogating of the Kb channel TREK-1. EMBO J. 2005;24:44-53.
31. Gozani O, Karuman P, Jones DR, et al. The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell. 2003;114:99-111.
32. Segade F, Gomez-Marquez J. Prothymosin alpha. Int J Biochem Cell Biol. 1999;31:1243-1248.
33. Letsas KP, Frangou-Lazaridis M. Surfing on prothymosin alpha proliferation and anti-apoptotic properties. Neoplasma. 2006;53: 92-96.
34. Covelo G, Sarandeses CS, Diaz-Jullien C, et al. Prothymosin alpha interacts with free core histones in the nucleus of dividing cells. J Biochem. 2006;140:627-637.
35. Karapetian RN, Evstafieva AG, Abaeva IS, et al. Nuclear oncoprotein prothymosin alpha is a partner of Keap1: implications for expression of oxidative stress-protecting genes. Mol Cell Biol. 2005;25:1089-1099.
36. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal. 2005;7:385-394. Review
37. Saito SY, Takeshima H. DNER as key molecule for cerebellar maturation. Cerebellum. 2006;5:227-231.
38. Dejda A, Sokolowska P, Nowak JZ. Neuroprotective role of PACAP, VIP, and PHI in the central nervous system. Pharmacol Rep. 2005;57:307-320.
39. Gozes I, Morimoto BH, Tiong J, et al. NAP: research and development of a peptide derived from activity-dependent neuro-protective protein (ADNP). CNS Drug Rev. 2005;11:353-368.
40. Steingart RA, Gozes I. Recombinant activity-dependent neuro-protective protein protects cells against oxidative stress. Mol Cell Endocrinol. 2006;252:148-153.
41. Zaltzman R, Alexandrovich A, Beni SM, et al. Brain injurydependent expression of activity-dependent neuroprotective protein. J Mol Neurosci. 2004;24:181-187.
42. Rotstein M, Bassan H, Kariv N, et al. NAP enhances neuro-development of newborn apolipoprotein E deficient mice subjected to hypoxia. J Pharmacol Exp Ther. 2006;319:332-339.
43. Sigalov E, Fridkin M, Brenneman DE, et al. VIP-related protection against lodoacetate toxicity in pheocromocytoma (PC12) cells: a model for ischemic/hypoxic injury. J Mol Neurosci. 2000;15: 147-154.